ArticleJournal of pharmacy & bioallied sciences2025
Efficacy of Immunotherapy in Treating Metastatic Melanoma: A Randomized Controlled Trial.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immunotherapy has revolutionized the treatment of metastatic melanoma, offering prolonged survival and improved outcomes. Checkpoint inhibitors like PD-1/PD-L1 have demonstrated significant efficacy in modulating the immune system's response to tumors. This randomized controlled trial aims to evaluate the efficacy of these therapies compared to standard care. Methods: A randomized trial was conducted on patients with advanced metastatic melanoma, who were assigned to either immunotherapy or traditional chemotherapy. Parameters included progression-free survival (PFS), overall survival (OS), and immune-related adverse events. Data analysis was conducted using appropriate statistical tests, with Results: Immunotherapy significantly improved PFS and OS compared to chemotherapy ( Conclusion: Immunotherapy provides a superior therapeutic option for patients with metastatic melanoma, offering improved survival outcomes with manageable toxicity. Further research is needed to refine patient selection and optimize treatment combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.